Svb Leerink reaffirmed their outperform rating on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a report issued on Monday, Zacks.com reports. Svb Leerink also issued estimates for Fulcrum Therapeutics’ Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at ($0.26) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($0.75) EPS, FY2020 earnings at ($2.48) EPS, FY2021 earnings at ($3.24) EPS, FY2022 earnings at ($3.02) EPS and FY2023 earnings at ($1.15) EPS.
A number of other brokerages also recently weighed in on FULC. Bank of America began coverage on shares of Fulcrum Therapeutics in a report on Monday. They set a buy rating and a $19.00 price target for the company. Morgan Stanley began coverage on shares of Fulcrum Therapeutics in a report on Monday. They set an overweight rating and a $29.00 price target for the company.
Shares of Fulcrum Therapeutics stock opened at $10.09 on Monday. Fulcrum Therapeutics has a 1-year low of $10.08 and a 1-year high of $15.94.
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.